Post-transplant lymphoproliferative disorders (PTLDs) are a group of conditions that involve uncontrolled proliferation of lymphoid cells as a consequence of extrinsic immunosuppression after organ or haematopoietic stem cell transplant. PTLDs show some similarities to classic lymphomas in the non-immunosuppressed general population. The oncogenic Epstein–Barr virus (EBV) is a key pathogenic driver in many early-onset cases, through multiple mechanisms. The incidence of PTLD varies with the type of transplant; a clear distinction should therefore be made between the conditions after solid organ transplant and after haematopoietic stem cell transplant. Recipient EBV seronegativity and the intensity of immunosuppression are among key risk factors. Symptoms and signs depend on the localization of the lymphoid masses. Diagnosis requires histopathology, although imaging techniques can provide additional supportive evidence. Pre-emptive intervention based on monitoring EBV levels in blood has emerged as the preferred strategy for PTLD prevention. Treatment of established disease includes reduction of immunosuppression and/or administration of rituximab (a B cell-specific antibody against CD20), chemotherapy and EBV-specific cytotoxic T cells. Despite these strategies, the mortality and morbidity remains considerable. Patient outcome is influenced by the severity of presentation, treatment-related complications and risk of allograft loss. New innovative treatment options hold promise for changing the outlook in the future.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $59.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Dharnidharka, V. R. & Araya, C. E. Post-transplant lymphoproliferative disease. Pediatr. Nephrol. 24, 731–736 (2009).
Singavi, A. K., Harrington, A. M. & Fenske, T. S. Post-transplant lymphoproliferative disorders. Cancer Treat. Res. 165, 305–327 (2015).
Al-Mansour, Z., Nelson, B. P. & Evens, A. M. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr. Hematol. Malig. Rep. 8, 173–183 (2013).
Green, M. & Michaels, M. G. Epstein–Barr virus infection and posttransplant lymphoproliferative disorder. Am. J. Transplant. 13 (Suppl. 3), 41–54; quiz 54 (2013).
Allen, U. D., Preiksaitis, J. K. & AST Infectious Diseases Community of Practice. Epstein–Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation. Am. J. Transplant. 13 (Suppl. 4), 107–120 (2013).
Doak, P. B., Montgomerie, J. Z., North, J. D. & Smith, F. Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy. Br. Med. J. 4, 746–748 (1968).
Starzl, T. E. et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1, 583–587 (1984). This seminal paper described how reduction of immunosuppression allowed for regression of PTLD through reconstitution of the immune system's control over EBV-infected proliferating B cells.
Campo, E. et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117, 5019–5032 (2011).
Quinlan, S. C., Pfeiffer, R. M., Morton, L. M. & Engels, E. A. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am. J. Hematol. 86, 206–209 (2011).
Dharnidharka, V. R. in Post-Transplant Lymphoproliferative Disorders (eds Dharnidharka, V. R., Green, M. & Webber, S. A. ) 17–28 (Springer-Verlag, 2009).
Luskin, M. R. et al. The Impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder. Am. J. Transplant. 15, 2665–2673 (2015).
Dharnidharka, V. R., Lamb, K. E., Gregg, J. A. & Meier-Kriesche, H. U. Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States. Am. J. Transplant. 12, 976–983 (2012).
Opelz, G. & Dohler, B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am. J. Transplant. 4, 222–230 (2004).
Rouce, R. H., Louis, C. U. & Heslop, H. E. Epstein–Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr. Opin. Hematol. 21, 476–481 (2014).
Webber, S. A. et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet 367, 233–239 (2006).
Kasiske, B. L. et al. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses. Am. J. Kidney Dis. 58, 971–980 (2011). This study compared two different methods of PTLD incidence and risk factor analysis, using two large national administrative registries that have different capture methods.
Faull, R. J., Hollett, P. & McDonald, S. P. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation 80, 193–197 (2005).
Trofe, J. et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am. J. Transplant. 5, 775–780 (2005).
Caillard, S., Lelong, C., Pessione, F. & Moulin, B. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am. J. Transplant. 6, 2735–2742 (2006).
Kinch, A. et al. Donor or recipient origin of posttransplant lymphoproliferative disorders following solid organ transplantation. Am. J. Transplant. 14, 2838–2845 (2014).
Sanz, J. et al. EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. Bone Marrow Transplant. 49, 397–402 (2014).
Olagne, J., Caillard, S., Gaub, M. P., Chenard, M. P. & Moulin, B. Post-transplant lymphoproliferative disorders: determination of donor/recipient origin in a large cohort of kidney recipients. Am. J. Transplant. 11, 1260–1269 (2011).
Dharnidharka, V. R., Tejani, A. H., Ho, P. L. & Harmon, W. E. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am. J. Transplant. 2, 993–998 (2002).
Green, M. et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am. J. Transplant. 6, 1906–1912 (2006).
Pirsch, J. D. Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U. S. multicenter FK506 Kidney Transplant Study Group. Transplantation 68, 1203–1205 (1999).
Kim, J. M. et al. Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia. Transplant. Proc. 42, 895–899 (2010).
Kisiel, E. et al. Seronegative hepatitis C virus infection in patients with lymphoproliferative disorders. J. Viral Hepat. 21, 424–429 (2014).
Martyak, L. A., Yeganeh, M. & Saab, S. Hepatitis C and lymphoproliferative disorders: from mixed cryoglobulinemia to non-Hodgkin's lymphoma. Clin. Gastroenterol. Hepatol. 7, 900–905 (2009).
Morton, L. M. et al. Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients. Blood 110, 4599–4605 (2007).
Arcaini, L. et al. Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection. Int. J. Cancer 124, 2246–2249 (2009).
Chen, W. et al. Complete absence of KSHV/HHV-8 in posttransplant lymphoproliferative disorders: an immunohistochemical and molecular study of 52 cases. Am. J. Clin. Pathol. 131, 632–639 (2009).
Du, M. Q., Bacon, C. M. & Isaacson, P. G. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J. Clin. Pathol. 60, 1350–1357 (2007).
Morscio, J., Dierickx, D. & Tousseyn, T. Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far? Clin. Dev. Immunol. 2013, 150835 (2013).
Tsao, L. & Hsi, E. D. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch. Pathol. Lab. Med. 131, 1209–1218 (2007).
Capello, D. et al. Analysis of immunoglobulin heavy and light chain variable genes in post-transplant lymphoproliferative disorders. Hematol. Oncol. 24, 212–219 (2006).
Uhlin, M. et al. Risk factors for Epstein–Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica 99, 346–352 (2014).
Babel, N. et al. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients. Transplantation 84, 387–391 (2007).
Reshef, R. et al. Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. Am. J. Transplant. 11, 817–825 (2011).
Babcock, G. J., Decker, L. L., Volk, M. & Thorley-Lawson, D. A. EBV persistence in memory B cells in vivo. Immunity 9, 395–404 (1998).
Babcock, G. J., Hochberg, D. & Thorley-Lawson, A. D. The expression pattern of Epstein–Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13, 497–506 (2000).
Langerak, A. W., Moreau, E., van Gastel-Mol, E. J., van der Burg, M. & van Dongen, J. J. Detection of clonal EBV episomes in lymphoproliferations as a diagnostic tool. Leukemia 16, 1572–1573 (2002).
Middeldorp, J. M., Brink, A. A., van den Brule, A. J. & Meijer, C. J. Pathogenic roles for Epstein–Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit. Rev. Oncol. Hematol. 45, 1–36 (2003).
Delecluse, H. J., Bartnizke, S., Hammerschmidt, W., Bullerdiek, J. & Bornkamm, G. W. Episomal and integrated copies of Epstein–Barr virus coexist in Burkitt lymphoma cell lines. J. Virol. 67, 1292–1299 (1993).
Ohshima, K., Suzumiya, J., Kanda, M., Kato, A. & Kikuchi, M. Integrated and episomal forms of Epstein–Barr virus (EBV) in EBV associated disease. Cancer Lett. 122, 43–50 (1998).
Reisinger, J., Rumpler, S., Lion, T. & Ambros, P. F. Visualization of episomal and integrated Epstein–Barr virus DNA by fiber fluorescence in situ hybridization. Int. J. Cancer 118, 1603–1608 (2006).
Chaganti, S. et al. Epstein–Barr virus colonization of tonsillar and peripheral blood B-cell subsets in primary infection and persistence. Blood 113, 6372–6381 (2009).
Timms, J. M. et al. Target cells of Epstein–Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. Lancet 361, 217–223 (2003). In this paper, the authors found that PTLD can arise not only from antigen-selected B memory cells but also from atypical B cells that have failed germinal centre selection, thus providing a pathogenesis link between PTLD and EBV-positive classical Hodgkin lymphoma in immunocompetent people.
Capello, D., Rossi, D. & Gaidano, G. Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Hematol. Oncol. 23, 61–67 (2005).
Bechtel, D., Kurth, J., Unkel, C. & Kuppers, R. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood 106, 4345–4350 (2005).
Price, A. M. & Luftig, M. A. To be or not IIb: a multi-step process for Epstein–Barr virus latency establishment and consequences for B cell tumorigenesis. PLoS Pathog. 11, e1004656 (2015).
Gires, O. et al. Latent membrane protein 1 of Epstein–Barr virus mimics a constitutively active receptor molecule. EMBO J. 16, 6131–6140 (1997).
Busch, L. K. & Bishop, G. A. The EBV transforming protein, latent membrane protein 1, mimics and cooperates with CD40 signaling in B lymphocytes. J. Immunol. 162, 2555–2561 (1999).
Uchida, J. et al. Mimicry of CD40 signals by Epstein–Barr virus LMP1 in B lymphocyte responses. Science 286, 300–303 (1999). The oncogene function of LMP1 was elucidated in this study that showed how LMP1 mimics CD40 signals to induce extrafollicular B cell differentiation but, unlike CD40, blocks germinal centre formation.
Young, L. et al. Expression of Epstein–Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N. Engl. J. Med. 321, 1080–1085 (1989).
Lambert, S. L. & Martinez, O. M. Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. J. Immunol. 179, 8225–8234 (2007).
Snow, A. L. et al. EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis. J. Immunol. 177, 3283–3293 (2006).
Vaysberg, M. et al. Tumor-derived variants of Epstein–Barr virus latent membrane protein 1 induce sustained Erk activation and c-Fos. J. Biol. Chem. 283, 36573–36585 (2008).
Snow, A. L. & Martinez, O. M. Epstein–Barr virus: evasive maneuvers in the development of PTLD. Am. J. Transplant. 7, 271–277 (2007).
Hatton, O. et al. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein–Barr virus+ (EBV+) B cell lymphomas. J. Biol. Chem. 286, 37368–37378 (2011).
Beatty, P. R., Krams, S. M. & Martinez, O. M. Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J. Immunol. 158, 4045–4051 (1997).
Zhang, B. et al. Immune surveillance and therapy of lymphomas driven by Epstein–Barr virus protein LMP1 in a mouse model. Cell 148, 739–751 (2012).
Grossman, S. R., Johannsen, E., Tong, X., Yalamanchili, R. & Kieff, E. The Epstein–Barr virus nuclear antigen 2 transactivator is directed to response elements by the Jκ recombination signal binding protein. Proc. Natl Acad. Sci. USA 91, 7568–7572 (1994).
Hsieh, J. J. & Hayward, S. D. Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein–Barr virus EBNA2. Science 268, 560–563 (1995).
Rabson, M., Gradoville, L., Heston, L. & Miller, G. Non-immortalizing P3J-HR-1 Epstein–Barr virus: a deletion mutant of its transforming parent, Jijoye. J. Virol. 44, 834–844 (1982).
Anderton, E. et al. Two Epstein–Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 27, 421–433 (2008).
Tomkinson, B., Robertson, E. & Kieff, E. Epstein–Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J. Virol. 67, 2014–2025 (1993).
Ohashi, M. et al. The EBNA3 family of Epstein–Barr virus nuclear proteins associates with the USP46/USP12 deubiquitination complexes to regulate lymphoblastoid cell line growth. PLoS Pathog. 11, e1004822 (2015).
Parker, G. A., Touitou, R. & Allday, M. J. Epstein–Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis. Oncogene 19, 700–709 (2000).
White, R. E. et al. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J. Clin. Invest. 122, 1487–1502 (2012).
Taylor, G. S., Long, H. M., Brooks, J. M., Rickinson, A. B. & Hislop, A. D. The immunology of Epstein–Barr virus-induced disease. Annu. Rev. Immunol. 33, 787–821 (2015).
Fish, K., Chen, J. & Longnecker, R. Epstein–Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma. Blood 123, 530–540 (2014).
Newell, E. W., Sigal, N., Bendall, S. C., Nolan, G. P. & Davis, M. M. Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. Immunity 36, 142–152 (2012).
Falco, D. A. et al. Identification of Epstein–Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients. Transplantation 74, 501–510 (2002).
Macedo, C. et al. EBV-specific memory CD8+ T cell phenotype and function in stable solid organ transplant patients. Transpl. Immunol. 14, 109–116 (2005).
Sebelin-Wulf, K. et al. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl. Immunol. 17, 203–210 (2007).
Macedo, C. et al. EBV-specific CD8+ T cells from asymptomatic pediatric thoracic transplant patients carrying chronic high EBV loads display contrasting features: activated phenotype and exhausted function. J. Immunol. 186, 5854–5862 (2011).
Green, M. R. et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin. Cancer Res. 18, 1611–1618 (2012).
Hinrichs, C. et al. IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment. Transpl. Int. 24, 892–903 (2011).
Baiocchi, O. C. et al. Epstein–Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: a nested case–control study in a renal transplant cohort. Leuk. Lymphoma 46, 533–539 (2005).
Birkeland, S. A., Bendtzen, K., Moller, B., Hamilton-Dutoit, S. & Andersen, H. K. Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. Transplantation 67, 876–881 (1999).
Harris-Arnold, A. et al. Epstein Barr virus modulates host cell microRNA-194 to promote IL-10 production and B lymphoma cell survival. Am. J. Transplant. 15, 2814–2824 (2015).
Tosato, G., Jones, K., Breinig, M. K., McWilliams, H. P. & McKnight, J. L. Interleukin-6 production in posttransplant lymphoproliferative disease. J. Clin. Invest. 91, 2806–2814 (1993).
Tosato, G., Tanner, J., Jones, K. D., Revel, M. & Pike, S. E. Identification of interleukin-6 as an autocrine growth factor for Epstein–Barr virus-immortalized B cells. J. Virol. 64, 3033–3041 (1990).
Haddad, E. et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter Phase 1–2 clinical trial. Blood 97, 1590–1597 (2001).
Horowitz, A. et al. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci. Transl Med. 5, 208ra145 (2013).
Lunemann, A., Vanoaica, L. D., Azzi, T., Nadal, D. & Munz, C. A distinct subpopulation of human NK cells restricts B cell transformation by EBV. J. Immunol. 191, 4989–4995 (2013).
Pappworth, I. Y., Wang, E. C. & Rowe, M. The switch from latent to productive infection in Epstein–Barr virus-infected B cells is associated with sensitization to NK cell killing. J. Virol. 81, 474–482 (2007).
Azzi, T. et al. Role for early-differentiated natural killer cells in infectious mononucleosis. Blood 124, 2533–2543 (2014).
Wiesmayr, S. et al. Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD. Eur. J. Immunol. 42, 541–550 (2012).
Miller, W. E., Cheshire, J. L., Baldwin, A. S. Jr & Raab-Traub, N. The NPC derived C15 LMP1 protein confers enhanced activation of NF-κB and induction of the EGFR in epithelial cells. Oncogene 16, 1869–1877 (1998).
Chang, C. M., Yu, K. J., Mbulaiteye, S. M., Hildesheim, A. & Bhatia, K. The extent of genetic diversity of Epstein–Barr virus and its geographic and disease patterns: a need for reappraisal. Virus Res. 143, 209–221 (2009).
Blake, N. et al. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7, 791–802 (1997).
Sandvej, K., Zhou, X. G. & Hamilton-Dutoit, S. EBNA-1 sequence variation in Danish and Chinese EBV-associated tumours: evidence for geographical polymorphism but not for tumour-specific subtype restriction. J. Pathol. 191, 127–131 (2000).
Gottschalk, S. et al. An Epstein–Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 97, 835–843 (2001).
Palser, A. L. et al. Genome diversity of Epstein–Barr virus from multiple tumor types and normal infection. J. Virol. 89, 5222–5237 (2015).
Tsai, M. H. et al. Spontaneous lytic replication and epitheliotropism define an Epstein–Barr virus strain found in carcinomas. Cell Rep. 5, 458–470 (2013).
Kwok, H. et al. Genomic diversity of Epstein–Barr virus genomes isolated from primary nasopharyngeal carcinoma biopsy samples. J. Virol. 88, 10662–10672 (2014).
Skalsky, R. L. et al. The viral and cellular microRNA targetome in lymphoblastoid cell lines. PLoS Pathog. 8, e1002484 (2012).
Pfeffer, S. et al. Identification of virus-encoded microRNAs. Science 304, 734–736 (2004).
Cullen, B. R. MicroRNAs as mediators of viral evasion of the immune system. Nat. Immunol. 14, 205–210 (2013).
Feederle, R. et al. A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus. PLoS Pathog. 7, e1001294 (2011).
Seto, E. et al. Micro RNAs of Epstein–Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog. 6, e1001063 (2010).
Qiu, J. et al. A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia. PLoS Pathog. 7, e1002193 (2011).
Qiu, J. & Thorley-Lawson, D. A. EBV microRNA BART 18-5p targets MAP3K2 to facilitate persistence in vivo by inhibiting viral replication in B cells. Proc. Natl Acad. Sci. USA 111, 11157–11162 (2014).
Alberghini, F., Petrocelli, V., Rahmat, M. & Casola, S. An epigenetic view of B-cell disorders. Immunol. Cell Biol. 93, 253–260 (2015).
Parker, A. et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients — BCSH and BTS Guidelines. Br. J. Haematol. 149, 675–692 (2010).
Fink, S. E. et al. A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors. Am. J. Transplant. 14, 2577–2587 (2014).
Richendollar, B. G. et al. Predictors of outcome in post-transplant lymphoproliferative disorder: an evaluation of tumor infiltrating lymphocytes in the context of clinical factors. Leuk. Lymphoma 50, 2005–2012 (2009).
Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059–3068 (2014).
Dierickx, D. et al. The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder. Haematologica 98, 771–775 (2013).
Panagiotidis, E. et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder. Leuk. Lymphoma 55, 515–519 (2014).
Gulley, M. L. & Tang, W. Using Epstein–Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin. Microbiol. Rev. 23, 350–366 (2010).
Preiksaitis, J. K. in Post-transplant Lymphoproliferative Disorders (eds Dharnidharka, V. R., Green, M. & Webber, S. A. ) 45–68 (Springer-Verlag, 2009).
San-Juan, R. et al. Epstein–Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clin. Microbiol. Infect. 20 (Suppl. 7), 109–118 (2014).
Tsai, D. E. et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am. J. Transplant. 8, 1016–1024 (2008).
Preiksaitis, J. K. et al. Interlaboratory comparison of Epstein–Barr virus viral load assays. Am. J. Transplant. 9, 269–279 (2009). The authors sent a blinded and fixed-quantity sample of EBV to several laboratories and found a profound variation in PCR assay results, eventually leading to the construction of an International EBV standard.
Hayden, R. T. et al. Multicenter comparison of different real-time PCR assays for quantitative detection of Epstein–Barr virus. J. Clin. Microbiol. 46, 157–163 (2008).
Fryer, J. F., Heath, A. B., Wilkinson, D. E., Minor, P. D. & The Collaborative Study Group Collaborative study to evaluate the proposed 1st WHO international standards for Epstein-Barr Virus (EBV) for Nucleic Acid Amplification Technology (NAT)-Based Assays. 1–43 (WHO Press, 2011).
Hayden, R. T. et al. Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis. J. Clin. Microbiol. 50, 337–345 (2012).
Greijer, A. E. et al. Variable EBV DNA load distributions and heterogeneous EBV mRNA expression patterns in the circulation of solid organ versus stem cell transplant recipients. Clin. Dev. Immunol. 2012, 543085 (2012).
Ruf, S. et al. Comparison of six different specimen types for Epstein–Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation. J. Clin. Virol. 53, 186–194 (2012).
van Esser, J. W. et al. Prevention of Epstein–Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99, 4364–4369 (2002).
Styczynski, J. et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 43, 757–770 (2009).
Patriarca, F. et al. Prognostic factors and outcome of Epstein–Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. Transpl. Infect. Dis. 15, 259–267 (2013).
Worth, A. et al. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein–Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br. J. Haematol. 155, 377–385 (2011).
Liu, Q. et al. Molecular monitoring and stepwise preemptive therapy for Epstein–Barr virus viremia after allogeneic stem cell transplantation. Am. J. Hematol. 88, 550–555 (2013).
van der Velden, W. J. et al. Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab. Bone Marrow Transplant. 48, 1465–1471 (2013).
Fox, C. P. et al. EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. Bone Marrow Transplant. 49, 280–286 (2014).
Wagner, H. J. et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 103, 3979–3981 (2004).
D'Aveni, M. et al. The clinical value of concomitant Epstein Barr virus (EBV)-DNA load and specific immune reconstitution monitoring after allogeneic hematopoietic stem cell transplantation. Transpl. Immunol. 24, 224–232 (2011).
Clave, E. et al. Epstein–Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 77, 76–84 (2004).
Smets, F. et al. Ratio between Epstein–Barr viral load and anti-Epstein–Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 73, 1603–1610 (2002).
Meij, P. et al. Impaired recovery of Epstein–Barr virus (EBV)—specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 101, 4290–4297 (2003).
Tischer, S. et al. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein–Barr virus-specific T cells as targets of interest in immunotherapeutic approaches. J. Immunol. Methods 408, 101–113 (2014).
Reddy, N., Rezvani, K., Barrett, A. J. & Savani, B. N. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol. Blood Marrow Transplant. 17, 591–597 (2011).
Green, M. & Michaels, M. in Post-transplant Lymphoproliferative Disorders (eds Dharnidharka, V. R., Green, M. & Webber, S. A. ) 133–142 (Springer-Verlag, 2009).
San-Juan, R. et al. Current preventive strategies and management of Epstein–Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey. Clin. Microbiol. Infect. 21, 604.e1–604.e9 (2015).
Krams, S. M. & Martinez, O. M. Epstein–Barr virus, rapamycin, and host immune responses. Curr. Opin. Organ Transplant. 13, 563–568 (2008).
Adamson, A. L., Le, B. T. & Siedenburg, B. D. Inhibition of mTORC1 inhibits lytic replication of Epstein–Barr virus in a cell-type specific manner. Virol. J. 11, 110 (2014).
Kirk, A. D. et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am. J. Transplant. 7, 2619–2625 (2007).
Choquet, S., Varnous, S., Deback, C., Golmard, J. L. & Leblond, V. Adapted treatment of Epstein–Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation. Am. J. Transplant. 14, 857–866 (2014).
Martin, S. I. et al. Monitoring infection with Epstein–Barr virus among seromismatch adult renal transplant recipients. Am. J. Transplant. 11, 1058–1063 (2011).
Vianna, R. M. et al. Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation. Transplantation 85, 1290–1293 (2008).
Dominietto, A. et al. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transplant. 47, 101–106 (2012).
Rooney, C. M., Leen, A. M., Vera, J. F. & Heslop, H. E. T lymphocytes targeting native receptors. Immunol. Rev. 257, 39–55 (2014).
Merlo, A., Turrini, R., Dolcetti, R., Zanovello, P. & Rosato, A. Immunotherapy for EBV-associated malignancies. Int. J. Hematol. 93, 281–293 (2011).
Ricciardelli, I. et al. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells. Blood 124, 2514–2522 (2014).
Leen, A. M. et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121, 5113–5123 (2013).
Opelz, G., Daniel, V., Naujokat, C., Fickenscher, H. & Dohler, B. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol. 8, 212–218 (2007).
Hocker, B. et al. (Val-)Ganciclovir prophylaxis reduces Epstein–Barr virus primary infection in pediatric renal transplantation. Transpl. Int. 25, 723–731 (2012).
Verghese, P. S., Schmeling, D. O., Knight, J. A., Matas, A. J. & Balfour, H. H. Jr. Valganciclovir administration to kidney donors to reduce the burden of cytomegalovirus and Epstein–Barr virus transmission during transplantation. Transplantation 99, 1186–1191 (2015).
Humar, A. et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein–Barr virus related posttransplant lymphoproliferative disorder. Transplantation 81, 856–861 (2006).
Cohen, J. I. Epstein–Barr virus vaccines. Clin. Transl. Immunology 4, e32 (2015).
Rees, L. et al. A Phase I trial of Epstein–Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 88, 1025–1029 (2009).
Tsai, D. E. et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 71, 1076–1088 (2001).
Choquet, S. et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter Phase 2 study. Blood 107, 3053–3057 (2006).
Gonzalez-Barca, E. et al. Prospective Phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 92, 1489–1494 (2007).
Choquet, S. et al. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 92, 273–274 (2007).
Trappe, R. et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre Phase 2 PTLD-1 trial. Lancet Oncol. 13, 196–206 (2012). This group performed the first ever multicentre prospective trial of PTLD treatment and showed that sequential treatment can achieve sustained remission in a sizeable majority of patients.
Trappe, R. U. et al. Response to rituximab induction is a predictive biomarker in post-transplant lymphoproliferative disorder (PTLD) and allows successful treatment stratification in an internatinoal Phase II trial including 152 patients. Blood 126, 816 (2015).
Meng, Q. et al. The Epstein–Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production. J. Virol. 84, 4534–4542 (2010).
Oertel, S. H., Anagnostopoulos, I., Hummel, M. W., Jonas, S. & Riess, H. B. Identification of early antigen BZLF1/ZEBRA protein of Epstein–Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease. Br. J. Haematol. 118, 1120–1123 (2002).
Gross, T. G. et al. Low-dose chemotherapy for Epstein–Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J. Clin. Oncol. 23, 6481–6488 (2005).
Gross, T. G. et al. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report. Am. J. Transplant. 12, 3069–3075 (2012).
Evens, A. M. et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. Am. J. Transplant. 13, 1512–1522 (2013).
Wall, S. M. et al. Effective clearance of methotrexate using high-flux hemodialysis membranes. Am. J. Kidney Dis. 28, 846–854 (1996).
Kuehnle, I. et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 95, 1502–1505 (2000).
Rasche, L., Kapp, M., Einsele, H. & Mielke, S. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT. Bone Marrow Transplant. 49, 163–167 (2014).
Karuturi, M. et al. Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients. Transpl. Int. 26, 616–622 (2013).
Perry, A. M. et al. Early onset, EBV, PTLD in pediatric liver-small bowel transplantation recipients: a spectrum of plasma cell neoplasms with favorable prognosis. Blood 121, 1377–1383 (2013).
Haque, T. et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a Phase 2 multicenter clinical trial. Blood 110, 1123–1131 (2007).
Papadopoulos, E. B. et al. Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330, 1185–1191 (1994).
Heslop, H. E., Brenner, M. K. & Rooney, C. M. Donor T cells to treat EBV-associated lymphoma. N. Engl. J. Med. 331, 679–680 (1994). This paper provided the first proof-of-concept that ex vivo-generated donor T cells could be produced to treat EBV-PTLD, with subsequent papers building on this concept.
Rooney, C. M. et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92, 1549–1555 (1998).
Heslop, H. E. et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115, 925–935 (2010).
Moosmann, A. et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 115, 2960–2970 (2010).
Uhlin, M. et al. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol. Immunother. 59, 473–477 (2010).
Dharnidharka, V. R., Martz, K. L., Stablein, D. M. & Benfield, M. R. Improved survival with recent post-transplant lymphoproliferative disorder (PTLD) in children with kidney transplants. Am. J. Transplant. 11, 751–758 (2011).
Carson, K. R. et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 10, 816–824 (2009).
Petropoulou, A. D. et al. Increased infection rate after preemptive rituximab treatment for Epstein–Barr virus reactivation after allogeneic hematopoietic stem-cell transplantation. Transplantation 94, 879–883 (2012).
Comoli, P. et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am. J. Transplant. 7, 1648–1655 (2007).
Yang, H. et al. Hyperexpression of Foxp3 and IDO during acute rejection of islet allografts. Transplantation 83, 1643–1647 (2007).
Trappe, R. U. et al. International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial. Am. J. Transplant. 15, 1091–1100 (2015).
Karras, A. et al. Successful renal retransplantation after post-transplant lymphoproliferative disease. Am. J. Transplant. 4, 1904–1909 (2004).
Johnson, S. R., Cherikh, W. S., Kauffman, H. M., Pavlakis, M. & Hanto, D. W. Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis. Am. J. Transplant. 6, 2743–2749 (2006). This large national registry study showed that PTLD recurrence was not seen in a re-transplant if PTLD had occurred in the failed prior transplant.
Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311–319 (2015).
Dharnidharka, V. R. & Mohanakumar, T. New approaches to treating B-cell cancers induced by Epstein–Barr virus. N. Engl. J. Med. 372, 569–571 (2015).
Espinoza, J. L., Takami, A., Trung, L. Q., Kato, S. & Nakao, S. Resveratrol prevents EBV transformation and inhibits the outgrowth of EBV-immortalized human B cells. PLoS ONE 7, e51306 (2012).
Xiang, Z. et al. Targeted activation of human Vγ9Vδ2-T cells controls Epstein–Barr virus-induced B cell lymphoproliferative disease. Cancer Cell 26, 565–576 (2014).
Glotz, D. et al. The Seville expert workshop for progress in posttransplant lymphoproliferative disorders. Transplantation 94, 784–793 (2012). In this paper, an expert multidisciplinary group highlight the current gaps in knowledge regarding PTLDs and provide recommendations for how to address them in future.
Dharnidharka, V. R., Douglas, V. K., Hunger, S. P. & Fennell, R. S. Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient. Pediatr. Transplant. 8, 87–90 (2004).
Thorley-Lawson, D. A. EBV persistence-introducing the virus. Curr. Top. Microbiol. Immunol. 390, 151–209 (2015).
Subklewe, M. et al. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation. Transplantation 82, 1093–1100 (2006).
Pourfarziani, V. et al. Associations of human leukocyte antigen (HLA) haplotypes with risk of developing lymphoproliferative disorders after renal transplantation. Ann. Transplant. 12, 16–22 (2007).
Poirel, H. A. et al. Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: correlation with histopathological subcategories and EBV status. Transplantation 80, 176–184 (2005).
Vakiani, E. et al. Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion. Hum. Pathol. 38, 315–325 (2007).
Djokic, M. et al. Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities. Genes Chromosomes Cancer 45, 313–318 (2006).
Jones, K. et al. HLA class I associations with EBV+ post-transplant lymphoproliferative disorder. Transpl. Immunol. 32, 126–130 (2015).
Leblond, V. et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J. Clin. Oncol. 19, 772–778 (2001).
Muti, G. et al. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica 87, 67–77 (2002).
Ghobrial, I. M. et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk. Lymphoma 46, 191–196 (2005).
Bakker, N. A. et al. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin. Transplant. 19, 327–334 (2005).
Ghobrial, I. M. et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J. Clin. Oncol. 23, 7574–7582 (2005).
Hourigan, M. J. et al. A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation. Br. J. Haematol. 141, 904–907 (2008).
Zimmermann, H. et al. Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial. Leukemia 27, 2102–2105 (2013).
S.C. reports receiving payments for consultancy, honoraria and advisory board membership from Roche. V.L. reports receiving payments for consultancy, honoraria and/or advisory board membership from Roche, Janssen, Mundipharma, Gilead and GSK. V.R.D. reports receiving payments for consultancy and honoraria from Bristol-Myers Squibb and Sanofi-Aventis, and research grant support from Novartis and Bristol-Myers Squibb. All other authors declare no competing interests.
About this article
Cite this article
Dharnidharka, V., Webster, A., Martinez, O. et al. Post-transplant lymphoproliferative disorders. Nat Rev Dis Primers 2, 15088 (2016). https://doi.org/10.1038/nrdp.2015.88
Infectious Agents and Cancer (2021)
EBV+ posttransplant lymphoproliferative disease of the retina presenting as cytomegalovirus retinitis
Annals of Hematology (2021)
Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry
Annals of Hematology (2021)
Pediatric Nephrology (2021)
Blood Cancer Journal (2020)